医学
免疫疗法
变应原免疫治疗
临床试验
医学物理学
替代医学
家庭医学
免疫学
内科学
病理
免疫系统
作者
Na Chen,Kun Zhang,Youwei Li,Ying Liu
出处
期刊:Allergologia et immunopathologia
[Codon Publications]
日期:2023-01-01
卷期号:51 (1): 63-73
被引量:1
标识
DOI:10.15586/aei.v51i1.714
摘要
Background: Allergic rhinoconjunctivitis (ARC) is a common chronic inflammatory disease. Numerous studies on the treatment of ARC have been published. By contrast, there are few bibliometric studies on immunotherapy for ARC. The purpose of this article is to describe the current treatments for ARC and to identify the trends in immunotherapy for ARC. Methods: Publications were searched from the Web of Science (WOS) Core Collection on April 25, 2022. CiteSpace and Microsoft Excel software were used for further bibliometric analysis. Results: A total of 969 publications on immunotherapy for ARC in English were retrieved. The number of relevant publications has been continuously increasing over the past 20 years, with many of the publications coming from Germany and the United States of America. In terms of institutions, the ALK Company in Denmark, Imperial College London in United Kingdom, and Charite–Universitatsmedizin Berlin in Germany published the most articles on immunotherapy for ARC. Meanwhile, Allergy and Journal of Allergy and Clinical Immunology published the most number of studies, and Oliver Pfaar from Germany authored the most number of articles. “Subcutaneous immunotherapy,” “international consensus,” “allergen immunotherapy,” and “recommendation” were the most popular subjects. Thus, directions in research can be predicted as studies regarding mechanisms of ARC, clinical trials, and extracts have reported high-quality results. Conclusion: Over the past 20 years, the overall quality of research on immunotherapy for ARC has gradually improved, allowing the introduction of specific and targeted treatment. Currently, the main focus of ARC research is the novel routes of drug delivery and combined treatment with biological agents.
科研通智能强力驱动
Strongly Powered by AbleSci AI